Mr Chee Khoon Lee

Clinical Lead
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 2 9562 5365

Map

Selected grants

2014

  • Does Palliative Chemotherapy Palliate Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study; Friedlander M, King M, Oza A, Ledermann J, O'Connell R, Sjoquist K, Martyn J, Lee C; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Hocking, C., Hardingham, J., Broadbridge, V., Wrin, J., Townsend, A., Tebbutt, N., Cooper, J., Ruszkiewicz, A., Lee, C., Price, T. (2014). Can we accurately report PTEN status in advanced colorectal cancer? BMC Cancer, 14(1), 1-7. [More Information]
  • Tjokrowidjaja, A., Lee, C., Houssami, N., Lord, S. (2014). Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis. Internal Medicine Journal, 44(8), 764-770. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1316. [More Information]
  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105(9), 595-605. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R., Murone, C., Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285. [More Information]
  • You, B., Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., et al (2013). The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecologic Oncology, 130(2), 289-294. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]
  • Verry, H., Lord, S., Martin, A., Gill, G., Lee, C., Howard, K., Wetzig, N., Simes, R. (2012). Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. British Journal of Cancer, 106(6), 1045-1052. [More Information]
  • Lee, C., Marschner, C., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]
  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Cummins, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
  • Lee, C., Lord, S., Coates, A., Simes, R. (2009). Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 190(11), 631-636. [More Information]
  • Chua, W., Goldstein, D., Lee, C., Dhillon, H., Michael, M., Mitchell, P., Clark, S., Iacopetta, B. (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 101(6), 998-1004. [More Information]
  • Lee, C., Hadley, A., DeSilva, K., Smith, G., Goldstein, D. (2009). When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis. World Journal of Surgical Oncology, 7(8), 1-4. [More Information]
  • Lord, S., Lee, C., Simes, R. (2008). The Role of Predictive and Prognostic Markers in Cancer. Cancer Forum, 32(3), 139-142.

Conferences

  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

2014

  • Hocking, C., Hardingham, J., Broadbridge, V., Wrin, J., Townsend, A., Tebbutt, N., Cooper, J., Ruszkiewicz, A., Lee, C., Price, T. (2014). Can we accurately report PTEN status in advanced colorectal cancer? BMC Cancer, 14(1), 1-7. [More Information]
  • Tjokrowidjaja, A., Lee, C., Houssami, N., Lord, S. (2014). Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis. Internal Medicine Journal, 44(8), 764-770. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1316. [More Information]

2013

  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105(9), 595-605. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R., Murone, C., Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285. [More Information]
  • You, B., Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., et al (2013). The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecologic Oncology, 130(2), 289-294. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]

2012

  • Verry, H., Lord, S., Martin, A., Gill, G., Lee, C., Howard, K., Wetzig, N., Simes, R. (2012). Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. British Journal of Cancer, 106(6), 1045-1052. [More Information]
  • Lee, C., Marschner, C., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]

2011

  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Cummins, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]

2010

  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]

2009

  • Lee, C., Lord, S., Coates, A., Simes, R. (2009). Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 190(11), 631-636. [More Information]
  • Chua, W., Goldstein, D., Lee, C., Dhillon, H., Michael, M., Mitchell, P., Clark, S., Iacopetta, B. (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 101(6), 998-1004. [More Information]
  • Lee, C., Hadley, A., DeSilva, K., Smith, G., Goldstein, D. (2009). When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis. World Journal of Surgical Oncology, 7(8), 1-4. [More Information]

2008

  • Lord, S., Lee, C., Simes, R. (2008). The Role of Predictive and Prognostic Markers in Cancer. Cancer Forum, 32(3), 139-142.

To update your profile click here. For support on your academic profile contact .